SynBac
Traditional process scale up using baculovirus is notoriously problematic, with yields dropping progressively during scale up. SynBac™ are minimized baculoviral genomes created using modern synthetic biology techniques. The SynBac™ project aims to transform fermenter-scale baculoviral production of drug targets, and manufacturing scale production of biopharmaceuticals by creating minimal baculoviral genomes displaying exceptional DNA stability. In addition to improved DNA stability, our minimized genomes form the starting point for applications that require large DNA cargo delivery to mammalian cells, primary cells, or organs.
17th Oct 2020
Recent Posts
-
CBM15: Shaping the Future of Glycosciences
The Carbohydrate Bioengineering Meeting XV (CBM15) is the leading platform for breakthroughs in glyc …3rd Dec 2024 -
Enhancing Immunoassays: Exploring the Utility of Camelid ELISA Kits in Biomedical Research
Introduction: Enzyme-Linked Immunosorbent Assay (ELISA) remains a cornerstone technique in biom …17th Apr 2024 -
Deciphering the Mechanisms of Dengue Virus-Like Particles (VLPs) for Advancing Vaccine Development: A Comprehensive Analysis
Dengue fever remains a significant global health concern, with millions of infections reported an …17th Apr 2024